Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Misinterpretation of MRI findings by clinicians focused on earlier intervention is leading to increased rates of ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Denmark's Novo Nordisk faces mounting pressure — from cheap copycats to US tariff threats — putting its weight-loss empire at ...

Big Pharma is using dark money to fund groups that sound like patient advocacy organizations but represent the industry.

Eli Lilly has ... next eight years. The alliance, dubbed the Lilly-Purdue 360 Initiative, will utilise advanced technologies such as artificial intelligence and machine learning to “accelerate ...

The initiative will also engage current joint programmes such as Lilly Scholars at Purdue and the Lilly and Purdue Research Alliance Center. Credit: Tada Images / Shutterstock. Eli Lilly and Purdue ..

INDIANAPOLIS and WEST LAFAYETTE, Ind. - Eli Lilly and Company (NYSE: LLY), a pharmaceutical giant with annual revenue exceeding $49 billion and an impressive 81.7% gross profit margin, and Purdue ...